Cite
HARVARD Citation
Kelley, R. et al. (2019). A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Clinical and translational gastroenterology. 10 (7), p. . [Online].